Sign in

Omega Healthcare Investors, Inc. OHI

Price 46.4 USD
as of 2026-09-05
54/100
Weak
Quality68
Growth74
Balance-sheet strength32
Valuation44
Momentum50
Income65

Composite 54/100; the shares have moved about 21% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.

Strongest counter-signal

Balance-sheet strength ranks 32/100 — a moderate mark against it.

Case for

Growth ranks 74/100 — a moderate point in its favour. Quality ranks 68/100 — a moderate point in its favour. Income ranks 65/100 — a moderate point in its favour.

Case against

Balance-sheet strength ranks 32/100 — a moderate mark against it. Valuation ranks 44/100 — a slight mark against it.

What the company does Omega Healthcare Investors (OHI) is a REIT focused on long-term healthcare real estate, primarily triple-net leased skilled nursing and assisted living facilities across the US, UK, and Canada.

Key financials OHI posts strong margins (gross 98.9%, operating 65.5%, net 51.4%) and solid returns (ROE 12.6%, ROA 4.9%, ROCE 9.3%). Revenue grew 14.3% and EPS 39.3%, with a 5.3% dividend yield and payout ratio 95.4%.

Stock health Sidera scores OHI 58.2 overall (Quality 66.2, Growth 72.4, Momentum 67.8, Income 76.8), but Valuation is weak at 38.5. Piotroski F-Score 6/9 and Altman Z 2.11 signal moderate financial health.

Price vs fair value OHI trades at a discount to both our fair-value estimate and analyst target. - Price is at a 48.00% discount to our fair-value estimate of 74.85. - Price is at a 1.81% discount to the 12-month target of 51.47 (19 analysts). - Recent Q2 2026 earnings and FFO/revenue beats (Zacks, GuruFocus) support near-term optimism.

Looking forward Forward P/E of 10.13 and PEG of 0.07 imply potential upside if growth sustains, though high payout ratio (95.4%) limits dividend flexibility.

sideravia.comEvery stock argues both sides.
Research, not advice · sideravia.com/conflicts — read the policy

This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.

Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.